Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Sell
38
ADUS Quote, Financials, Valuation and Earnings
Last price:
$101.33
Seasonality move
:
13.28%
Day range:
$97.58 - $100.24
52-week range:
$87.88 - $136.72
Dividend yield:
0%
P/E ratio:
23.56x
P/S ratio:
1.50x
P/B ratio:
1.87x
Volume:
192K
Avg. volume:
256.5K
1-year change:
-1.75%
Market cap:
$1.8B
Revenue:
$1.2B
EPS (TTM):
$4.24
Analysts' Opinion
-
Consensus RatingAddus HomeCare has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $136.27, Addus HomeCare has an estimated upside of 36.44% from its current price of $99.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $83.00 representing 100% downside risk from its current price of $99.88.
Fair Value
-
According to the consensus of 8 analysts, Addus HomeCare has 36.44% upside to fair value with a price target of $136.27 per share.
ADUS vs. S&P 500
-
Over the past 5 trading days, Addus HomeCare has overperformed the S&P 500 by 2.23% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Addus HomeCare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Addus HomeCare has grown year-over-year revenues for 49 quarters straight. In the most recent quarter Addus HomeCare reported revenues of $297.1M.
Earnings Growth
-
Addus HomeCare earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Addus HomeCare reported earnings per share of $1.07.
Enterprise value:
1.9B
EV / Invested capital:
--
Price / LTM sales:
1.50x
EV / EBIT:
18.07x
EV / Revenue:
1.68x
PEG ratio (5yr expected):
2.26x
EV / Free cash flow:
17.53x
Price / Operating cash flow:
15.71x
Enterprise value / EBITDA:
16.04x
Gross Profit (TTM):
$375M
Return On Assets:
6.43%
Net Income Margin (TTM):
6.37%
Return On Equity:
8.62%
Return On Invested Capital:
7.81%
Operating Margin:
9.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $951.1M | $1.1B | $1.2B | $276.4M | $297.1M | |
| Gross Profit | $299.7M | $339.9M | $375M | $92.4M | $101.5M | |
| Operating Income | $68.7M | $91M | $102.7M | $28M | $26.9M | |
| EBITDA | $83.1M | $106.6M | $120.6M | $32.1M | $31.7M | |
| Diluted EPS | $2.85 | $3.84 | $4.24 | $1.20 | $1.07 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $287.7M | $324.3M | $222.8M | $200M | $260.4M | |
| Total Assets | $892.6M | $947.6M | $938M | $1B | $1.4B | |
| Current Liabilities | $143.9M | $117.7M | $131.1M | $145.1M | $155.9M | |
| Total Liabilities | $373.9M | $373.2M | $304.5M | $317.7M | $442.1M | |
| Total Equity | $518.7M | $574.3M | $633.5M | $706.7M | $970.5M | |
| Total Debt | $194.9M | $220.9M | $131.8M | $124.1M | $218.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $105.1M | $112.2M | $116.4M | $30M | $10.4M | |
| Cash From Investing | -$106.6M | -$119.2M | -$354.6M | -$5.3M | -$354.5M | |
| Cash From Financing | -$87.5M | -$8.2M | $272.3M | -$39.7M | $220.1M | |
| Free Cash Flow | $96.8M | $102.8M | $110.4M | $24.7M | $8.7M | |
ADUS
Sector
Market Cap
$1.8B
$35.9M
Price % of 52-Week High
73.05%
43.21%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-1.75%
-43.29%
Beta (5-Year)
0.935
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$96.87
200-day SMA
Sell
Level
$121.17
Bollinger Bands (100)
Sell
Level
102.67 - 130.61
Chaikin Money Flow
Buy
Level
11.8M
20-day SMA
Buy
Level
$94.43
Relative Strength Index (RSI14)
Buy
Level
53.82
ADX Line
Buy
Level
35.62
Williams %R
Sell
Level
-6.5068
50-day SMA
Sell
Level
$107.91
MACD (12, 26)
Sell
Level
-2.00
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
19.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.6164)
Buy
CA Score
(Annual)
Level (1.1672)
Buy
Beneish M-Score
(Annual)
Level (-2.5511)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.352)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
Stock Forecast FAQ
In the current month, ADUS has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADUS average analyst price target in the past 3 months is $136.27.
-
Where Will Addus HomeCare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Addus HomeCare share price will rise to $136.27 per share over the next 12 months.
-
What Do Analysts Say About Addus HomeCare?
Analysts are divided on their view about Addus HomeCare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Addus HomeCare is a Sell and believe this share price will drop from its current level to $83.00.
-
What Is Addus HomeCare's Price Target?
The price target for Addus HomeCare over the next 1-year time period is forecast to be $136.27 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ADUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Addus HomeCare is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADUS?
You can purchase shares of Addus HomeCare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Addus HomeCare shares.
-
What Is The Addus HomeCare Share Price Today?
Addus HomeCare was last trading at $101.33 per share. This represents the most recent stock quote for Addus HomeCare. Yesterday, Addus HomeCare closed at $99.88 per share.
-
How To Buy Addus HomeCare Stock Online?
In order to purchase Addus HomeCare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
